Background Mapping is an increasingly common method used to predict instrument-specific preference-based health-state utility values (HSUVs) from data obtained from another health-related quality of life (HRQoL) measure. There have been several methodological developments in this area since a previous review up to 2007. Objective To provide an updated review of all mapping studies that map from HRQoL measures to target generic preferencebased measures (EQ-5D measures, SF-6D, HUI measures, QWB, AQoL measures, 15D/16D/17D, CHU-9D) published from January 2007 to October 2018. Data sources A systematic review of English language articles using a variety of approaches: searching electronic and utilities databases, citation searching, targeted journal and website searches. Study selection Full papers of studies that mapped from one health measure to a target preference-based measure using formal statistical regression techniques. Data extraction Undertaken by four authors using predefined data fields including measures, data used, econometric models and assessment of predictive ability. Results There were 180 papers with 233 mapping functions in total. Mapping functions were generated to obtain EQ-5D-3L/ EQ-5D-5L-EQ-5D-Y (n = 147), SF-6D (n = 45), AQoL-4D/AQoL-8D (n = 12), HUI2/HUI3 (n = 13), 15D (n = 8) CHU-9D (n = 4) and QWB-SA (n = 4) HSUVs. A large number of different regression methods were used with ordinary least squares (OLS) still being the most common approach (used ≥ 75% times within each preference-based measure). The majority of studies assessed the predictive ability of the mapping functions using mean absolute or root mean squared errors (n = 192, 82%), but this was lower when considering errors across different categories of severity (n = 92, 39%) and plots of predictions (n = 120, 52%). Conclusions The last 10 years has seen a substantial increase in the number of mapping studies and some evidence of advancement in methods with consideration of models beyond OLS and greater reporting of predictive ability of mapping functions.
Introduction
Resource allocation decisions in healthcare are frequently informed by Health Technology Assessment (HTA) using cost-effectiveness analysis where benefits are measured using quality-adjusted life years (QALYs). QALYs are a measure that combine both health-related quality (HRQoL) and quantity of life, and can be used across patient groups and interventions, reflecting both changes in HRQoL and life expectancy. QALYs are generated by multiplying a qualityadjustment weight (health-state utility value (HSUV)) for health by duration, where the HSUV is often measured using a preference-based measure (PBM).
PBMs are made up of a descriptive system that describes HRQoL based on dimensions such as physical functioning, pain, social functioning and emotional functioning, and with severity levels within each dimension. This allows HRQoL to be classified using a combination of the dimensions and
Key Points for Decision-Makers
Mapping or cross-walking enables utility values to be generated from other health-related quality-of-life measures in studies where the preferred preference-based measure has not been used.
This updated review shows that compared to 10 years ago, there are now many mapping functions (n = 233 across 180 published studies) that can be used to generate utility values from a large number of measures, with the majority being to EQ-5D-3L.
Mapping studies now report important information that enable decision-makers to better understand and interpret mapped utility estimates, but mapping remains a second-best alternative to using the preference-based measures directly.
PBMs vary with respect to the descriptive systems and the value sets. International agencies that review HTA evidence to inform resource allocation decisions often recommend the use of a particular PBM to generate QALYs [17] . For example, the National Institute for Health and Care Excellence (NICE) recommend that EQ-5D-3L is used in England [18] and the National Health Care Institute (Zorginstituut (ZIN)) recommends the EQ-5D-5L in the Netherlands [19] . Furthermore, many international agencies recommend that PBMs are scored using their own country value set, for example the Pharmaceutical Benefits Advisory Committee (PBAC) in Australia recommend that HSUVs are generated using Australian general population preference weights [20] , and the same requirement is also recommended for France [21] , the Netherlands [22] , Spain [23] , England [18] and Canada [24] . However, many clinical effectiveness studies that are used to inform HTA either do not include PBMs or do not include the PBM that is preferred by the target reimbursement authority. This has led to a rapid increase in the number of mapping papers published in recent years that estimate functions to predict HSUVs.
A mapping function is a prediction equation that is generated using the statistical relationship between a measure, referred to as the start measure that is used in the study of interest and a target PBM (e.g. EQ-5D-3L), estimated using regression analyses [25, 26] . The mapping function is then applied in the study of interest to predict the target PBM, where the target PBM has not been administered directly. There are a number of considerations when undertaking mapping (see for example Longworth and Rowen [25] , Wailoo et al. [27] and Ara et al. [26] ).
Conceptual overlap between the start measure and the target PBM is an important consideration before mapping can be undertaken [28] . For example, if the target PBM covers generic aspects of HRQoL such as physical, mental and social functioning, then the source measure should also have questions and/or dimensions that would be mapped onto these concepts. Regression analysis relies on the existence of a relationship between the two measures, and where there is little conceptual overlap, mapping will not be a suitable solution for generating HSUVs. Beyond this, there are a number of methodological choices that can have an impact on the resultant mapping functions. The dataset used to undertake mapping is usually a convenient pre-existing dataset that has both the start measure and the target PBM, such as a trial or observational study. It is important to consider whether the available dataset provides what is required to generate mapping functions that are appropriate for the population to which it will be applied, for example the range in clinical severity and age. Depending on the sample size, regression analysis can be used to obtain mapping functions to predict either HSUVs or the individual health dimensions of the PBM, typically referred to as response mapping. A larger severity levels in each dimension. For example, EQ-5D-3L has five dimensions (mobility, self-care, usual activities, pain/discomfort, anxiety/depression) each with three levels of severity (none, moderate, severe), which results in 243 health states that can be used to describe HRQoL [1] . Descriptive systems for PBMs have a HSUV on a 0 (dead) to 1 (full health) scale, with some measures having negative values for health states considered to be worse than dead. The HSUVs are usually derived from representative members of the general public who complete a preference elicitation task such as time trade off (TTO) or standard gamble (SG) to generate a value set. Patients complete the PBM and the value set is then applied to their responses to generate HSUVs.
Generic PBMs can be used across different conditions while condition-specific PBMs are specific to a condition [2] . The focus here is on generic PBMs. There are a number of generic PBMs, with the most commonly used being the EQ-5D-3L [3] , though there is a new five-level version, the EQ-5D-5L [1] . The other measures include the SF-6D [4, 5] , the Health Utilities Index (HUI2 [6] and HUI3 [7] ), the Assessment of Quality of Life measures (AQoL-4D, AQoL-6D and AQoL-8D) [8] , the 15D [9] and the Quality of Wellbeing-Self Administered (QWB-SA) [10] . The majority of PBMs are adult measures, although there are child or adolescent versions: 16D and 17D [11, 12] and EQ-5D-Y [13] ; while AQoL-6D has been adapted for use in adolescent populations [14] . HUI2 was originally designed for children, and the original version of QWB-SA was tested in both adult and child populations [15] . The Child Health Utility 9 dimensions (CHU-9D) is another generic measure developed specifically for use in children [16] . dataset covering the full range of severity is usually required for response mapping to enable all the severity levels within each dimension of the PBM to be estimated. The benefit of response mapping is that individual country value sets can be applied to the predicted dimensions, whereas mapping to the HSUVs restricts the predictions to the specific country value set used in the regression analyses.
In addition to the choice of whether to predict HSUVs or responses to the dimensions, analysts also have a choice with regard to whether to use overall scores, dimension scores or items from the start measure as predictor variables. Age and gender may be considered important, and their inclusion has been recommended where available [27] . Other variables such as clinical outcomes could also be included, although the choice is partly determined by what variables are available in both datasets, for example if only dimension scores, age and gender are available, then the mapping function can only use these variables.
There are also options regarding which regression method to use. A previous systematic review [29] found the most common approach when mapping to HSUVs was ordinary least squares (OLS), but other approaches that reflect the distribution of the HSUVs had also been applied. These included Tobit and Censored Least Absolute Deviation (CLAD) to deal with the limited range of the HSUVs as their maximum value is 1. More recently, methods have been developed to deal with multi-modal distributions such as mixture models, and methods that combine different approaches such as the adjusted limited dependent variable mixture models (ALDVMM) [26, 27] . Techniques such as ordered logit or probit and multinomial logit or probit have been used for response mapping to PBM dimensions.
Finally, there are different statistics that can be used to assess the predictive abilities of the mapping functions. Much of the focus is on how well the mapping functions predict HSUVs compared to the observed HSUVs, since this is indicative of the accuracy of the mapping function at predicting utilities in another dataset. Errors can be generated that report the difference between observed and predicted HSUVs. However, mean errors can mask large differences where both positive and negative differences exist as well as masking any bias in errors, for example, larger errors at the extremes of HSUVs index. Therefore, other measures of error such as mean absolute errors (MAEs), mean squared errors (MSEs) or root mean squared errors (RMSEs) are preferred [25, 26] . These provide an assessment of the difference between predicted and observed values, with smaller values preferred. Assessment of performance may be within the dataset used to predict the function or a separate dataset, with the latter usually based on a smaller subset of the predicted dataset that is not used in the prediction. The statistics on errors can also be presented based on severity either by HSUVs or by a different measure of severity such as a clinical measure. This is useful as there is evidence that errors may be associated with severity and the analysis can be informative for users of the mapping function. Plots of the predicted and observed HSUVs alongside corresponding errors are also informative. Studies may also assess results based on the expected sign, statistical significance and consistency of estimated coefficients for the explanatory variables.
The previous Brazier et al. [29] systematic review found 30 studies reporting functions mapping from nonpreference-based measures to PBMs in studies published before 2007 [29] . The most common technique was ordinary least squares (OLS), with very few studies using any other approaches. Most of the studies reported R-squared values, mean errors and overall RMSEs or MSEs. This previous review recommended that research should be undertaken to test the accuracy of mapping functions, and that a framework should be developed for the critical appraisal of mapping studies to enable policy makers to critically assess HSUVs generated using mapping studies. Since that time a large number of mapping studies have been published, and the methods to estimate mapping functions have increased. Several papers that make recommendations around the estimation of mapping functions including data requirements, regression models, performance assessment and reporting standards have also been published [25] [26] [27] 30] . In addition, a database developed by researchers at the Health Economics Research Centre (HERC) at Oxford University for studies mapping to EQ-5D measures is available [31] . This provides a valuable resource for researchers searching for appropriate mapping functions for EQ-5D. However, although the database includes other PBMs where they have been included in studies mapping to EQ-5D measures, it does not include studies that only map to other PBMs, which may be useful for other international agencies beyond the UK. One aim of this review was to address this gap.
The overall objective of this paper was to update the 2010 mapping review [29] to identify studies that map to generic adult and child PBMs from other HRQoL measures including other preference-based measures. This would provide a resource for researchers searching for studies that estimate mapping functions that are appropriate for use in their context in order to meet particular international reimbursement agency requirements.
Methods

Database and Search Terms
The search strategy consisted of five different searches: electronic databases, utilities databases, citation searching of key publications, targeted journal searching and targeted website searching. The search was limited by publication date from January 2007 to October 2018. Three electronic databases were searched: MEDLINE, Web of Science and the Cumulative Index to Nursing and Allied Health Literature (CINAHL). The search strategy used free-text synonyms for generic preference-based measures of interest 'EQ-5D, SF-6D, HUI measures, QWB, AQoL measures, 15D/16D/17D and CHU-9D'. This was combined with freetext terms for map*, crosswalk*, cross walk*, cross-walk*, estimat* or predict*, transfer, transformation or deriv*. The search strategy used here differs from the original review, which did not include all the generic preference-based measures in the search terms, but had EQ-5D, HUI and QWB. Searches were used across databases and were limited to English language publications. The search strategies are presented in Appendix 1.
Two utilities databases were searched: the HERC database of mapping [31] and the ScHARR Health State Utilities Database (ScHARRHUD) [32] , a searchable database providing published HSUVs. Free-text terms for map*, crosswalk*, cross walk*, cross-walk*, estimat* or predict*, transfer, transformation or deriv* in the title field was applied. Citation searches were undertaken based on the previously published mapping review [29] in the Scopus (Elsevier) database. Citation searches were also undertaken in the Web of Science (Clarivate Analytics), Scopus (Elsevier) and Google Scholar for four mapping reviews [33] [34] [35] [36] and three mapping guidelines [27, 30, 37] .
Based on the previous review, four journals that have previously published the mapping papers were searched in the Web of Science (Thomson Reuter): (1) Medical Decision Making, (2) Value in Health, (3) Medical Care and (4) Journal of Health Economics. The search strategy is presented in Appendix 1. Relevant websites included the ISPOR website via the ISPOR Scientific Presentations Database [38] and EuroQoL (developers of EQ-5D measures) website [39] . The search strategies are presented in Appendix 3.
Inclusion Criteria
Studies that undertook statistical mapping between one HRQoL measure and one of the target generic PBMs (EQ-5D-3L/EQ-5D-5L/EQ-5D-Y, SF-6D, HUI2/HUI3, QWB-SA, AQoL-4D, AQoL-6D/AQoL-8D, 15D/16D/17D, CHU-9D) were included. This included mapping between preference-based measures. Only English language studies were included. There were no restrictions with regard to the population.
The primary interest was mapping between measures with reported mapping functions that could be applied with specific focus on generic PBMs. Conference abstracts, studies mapping to directly elicited HSUVs generated using valuation techniques such as visual analogue scale or time trade off (i.e. not to utility values generated using a generic preference-based measure), studies not using HRQoL measures as the start measure and studies mapping to condition specific PBMs were excluded. Studies that undertook factor analysis were also excluded as they are not used to predict utility values. Methodology studies were excluded where they did not provide mapping functions. Studies that only applied or tested existing functions were also excluded.
Measures
The review focuses on mapping studies where the target measure is any one of the following generic PBMs: EQ-5D-3L/EQ-5D-5L/EQ-5D-Y, SF-6D, HUI2/HUI3, AQoL-4D/AQoL-6D/AQoL-8D, 15D/16D/17D, QWB-SA and CHU-9D.
EQ-5D Measures
EQ-5D is the most widely used generic PBM with threelevel (3L) [3] and five-level (5L) [1] versions. Both versions have the same five dimensions: mobility, self-care, usual activities, pain/discomfort and anxiety/depression, but have different levels (3/5) of severity. The EQ-5D-3L has the following severity levels: none, moderate and severe; while the EQ-5D-5L has the following severity levels: none, slight, moderate, severe and unable/extreme. Preferences for the EQ-5D-3L have been derived using TTO as well as the visual analogue scale (VAS) and more recently for the EQ-5D-5L using discrete choice experiments (DCEs). Value sets are available for 32 countries for the EQ-5D-3L and for 14 countries for the EQ-5D-5L [39] . In addition, there is a cross-walk algorithm that has been used to generate 3L HSUVs from the 5L descriptive system while value sets are under development [40] . This mapping algorithm can be used to generate utility values for Denmark, France, Germany, Japan, the Netherlands, Spain, Thailand, the UK, the USA and Zimbabwe. The mapping algorithm has also been applied to Sri-Lankan [41] and Polish [42] EQ-5D-3L utility values as it maps to the health states not utility values. There is also a youth version EQ-5D-Y, which was developed from the EQ-5D-3L for use in children and adolescents [13] . However, there are no HSUVs available for this measure and most studies apply adult HSUVs.
SF-6D
The SF-6D is a preference-based measure derived from the SF-36 and the SF-12. SF-36 is a non-preference-based HRQoL measure with 36 questions with eight dimensions and physical and mental health summary scores [43] . It is one of the most commonly used health measures. SF-12 is a shorter version derived from the SF-36 covering the same dimensions. The SF-6D has six dimensions: physical functioning, role limitation, social functioning, pain, energy and mental health. Each dimension has between four and six severity levels [4] . SF-6D can describe 18,000 possible unique health states for the version obtained from the SF-36 [4] and 7500 possible unique health states for the version derived from the SF-12 [5] . Value sets are available for Australia [44] , Brazil [45] , China (Hong Kong) [46] , Japan [47] , Portugal [48] , Spain [49] and the UK [4, 5] , where values were elicited using SG or DCE.
HUI2 and HUI3
The HUI2 and HUI3 are both derived from the same 15-item self-completed questionnaire. The HUI2 was originally developed for use in paediatric oncology. HUI2 has six dimensions: sensation, mobility, emotion, cognition, selfcare and pain (fertility is an extra dimension that is not commonly used), each with four or five severity levels resulting in 8000 health states [6] . HUI3 has eight dimensions: vision, hearing, speech, ambulation, dexterity, emotion, cognition and pain, each with five or six severity levels resulting in 972,000 health states [7] . Value sets are available for Canada [6] and the UK [50] for HUI2, and for Canada [7] , France [51] and Spain [52] for HUI3 using values elicited using VAS and SG or SG on its own.
15D, 16D and 17D
The 15D has 15 dimensions: mobility, vision, hearing, breathing, sleeping, eating, speech, excretion, usual activities, mental function, discomfort and symptoms, depression, distress, vitality, sexual activity [9] . Each dimension has five severity levels, resulting in 5 × 10 15 health states. The value set was generated using VAS values elicited in Finland [9] , with a recent value set generated using VAS for Norway [53] .
The 16D (for adolescents aged 12-15 years) [11] and the 17D (for children aged 8-11 years) [12] were developed based on the 15D. The value set was generated using VAS with Finnish children aged 12-15 for the 16D while parents provided VAS values for the 17D.
AQoL Measures
The Assessment of Quality of Life has different versions that can be used including the AQoL-4D, AQoL-6D and the AQoL-8D with a different number of dimensions for each version [8, 54, 55] . AQoL-4D has four dimensions (independent living, senses, relationships and mental health), while AQoL-6D has six dimensions (independent living, mental health, coping, relationships, pain and senses). The latest version, the AQoL-8D, has eight dimensions: independent living, happiness, mental health, coping, relationships, self-worth, pain and senses, which are based on a combination of a 35-item questionnaire resulting in 2.37 × 10 23 health states [8] . The value set is generated using VAS and TTO values elicited in Australia.
AQoL-6D has also been adapted for use with adolescents. Value sets for the adapted AQoL-6D were generated using TTO in a sample of adolescents from Australia, Fiji, New Zealand and Tonga [14] .
QWB-SA
The QWB-SA has 68 items in total with dichotomous symptom lists for 19 chronic symptoms, 25 acute symptoms and 14 mental health symptoms/behaviours, along with 17 items that cover mobility and physical and social activity [56, 57] . The original version was developed and tested for use in both adults and children [15] . It defines 945 health states, and the value set is generated using VAS values elicited in the USA.
CHU-9D
The Child Health Utility Index 9D (CHU-9D) has nine dimensions: worry, sadness, annoyance, tiredness, pain, sleep, daily routine, school and activities [16] . Each dimension has five levels of severity resulting in 1953,125 health states. The value set has been generated using SG in the UK using an adult sample [58] , best-worst scaling (BWS) in Australia using an adolescent and adults [59, 60] and BWS with TTO in a sample of adolescents in China [61] .
Study Selection
Three authors undertook study selection. SH undertook an initial eligibility assessment across all of the identified studies, excluding studies that were identified as not mapping studies from titles. CM and DR undertook further eligibility assessment based on abstracts and the full-paper review. Queries were discussed between the reviewers.
Data Extraction and Analysis
An extraction template was created by DR and reviewed by the team. The final template included information on the start measure and the target PBM, whether measures were self-completed, the country value set used and whether mapping was done to the HSUV index or the dimensions. Details about the estimation dataset including the population, for example patient characteristics, the sample country and the sample size were extracted. For methods, the regression techniques were extracted and whether additional explanatory variables (clinical, age, gender) were recorded. Whether the regression coefficients were reported was noted.
Information on how studies assessed performance of the mapping functions including MAE/MSE/RMSE, including by severity, and plots of predictions was also noted. Actual values, for example regression coefficients or MAEs, were not extracted. Independent extraction was undertaken by AR, CM, DR and SH. AR, SH and CM did initial extraction and CM and DR double-checked the extractions.
Analysis was based on the number of studies across the preference-based measures as well as in relation to methods used. The Brazier et al. [29] review noted that OLS was the most common method, but they noted the limitation of using OLS for mapping. R-squared was also reported in studies in the previous review, but this does not provide useful information on whether mapping functions are valid and was not extracted for this review. Therefore, we considered what type of regression methods were used and what information was used in comparison of mapping functions, i.e. use of MAE/RMSE or plots. No quality assessments were made with regard to the reported mapping functions as judgements about the validity of mapping functions depend in part on the context in which they will be applied.
Results
Studies Included
A total of 2967 papers were identified from the different sources after removal of 2444 duplicates (Fig. 1) . The number of relevant papers was reduced to 1278 based on a review of the titles and a further 707 were excluded based on review of abstracts. Further review of the remaining full papers resulted in a total of 180 papers (Fig. 1). 
General Description of Studies
The mapping functions are presented in Appendix 2 ordered by the target PBM then the source measure. Some papers reported mapping functions to more than one PBM. Where a study reports a mapping to a single PBM, this was counted as a single mapping function even where different regression methods were used or different specifications tested. Where papers reported mapping to more than one PBM, for example to EQ-5D-3L and to SF-6D, this was counted as two mapping functions. There were 233 mapping functions published across the 180 papers. Highlighted rows indicate mapping functions reported in papers that estimate mapping functions to more than one PBM.
There were eight different 15D mapping functions, 12 for AQoL measures, four for CHU-9D, 147 for EQ-5D measures, 13 for HUI measures, four for QWB-SA and 45 for SF-6D. For AQoL, four were mapping functions to AQoL-4D while the rest were to AQoL-8D. EQ-5D mapping functions were mainly to EQ-5D-3L (n = 124), with 22 mapping functions to EQ-5D-5L and 1 to EQ-5D-Y. There were two mapping functions that used HUI2 and there were 12 mapping functions using HUI3.
The majority of the mapping functions were between non-preference-based measures and the target PBM (Appendix 2). The most common condition-specific non-preferencebased start measures were the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire (EORTC QLQ C30) [240] used in 25 mapping functions, variations of the Functional Assessment of Cancer Therapy (FACT) [241] including the general version, breast cancer, melanoma and prostate cancer (n = 12), and the Health Assessment Questionnaire (HAQ) including HAQDisability index [242] for rheumatoid arthritis (n = 13). The rest of the start measures included condition-specific HRQoL measures for a number of different conditions. There were also generic non-preference-based HRQoL measures used as the start measure including the SF-12 or SF-36 [43, 243] (n = 12), the Nottingham Health Profile [244] (n = 2), the Patient Reported Outcomes Measure Information Systems (PROMIS) [245] (n = 4) and the WHO-QoL BREF [246] (n = 4). One study used a measure for older people (Older People's Quality of Life Brief Questionnaire [247] ) and one used a measure for women (Women's Health Questionnaire-23 [248] ) to generate two mapping functions. One study used a general health or self-assessed health question [122] .
The generic PBMs (15D, AQoL-8D, HUI3, QWB-SA, SF-6D, EQ-5D-3L/EQ-5D-5L) were also used as start measures. Two papers provided mapping functions between these six generic PBMs [62, 63] . Two papers mapped between EQ-5D-3L and EQ-5D-5L [40, 203] .
For mapping functions to CHU-9D, there were two generic measures, the KIDSCREEN [249] and the Pediatric Quality of Life Inventory (PedsQL) [250] , one mental health measure (Strengths and Difficulties Questionnaire [251] ) and one weight measure (Weight-Specific Adolescent Instrument for Economic Evaluation (WAItE) [252] ). The PedsQL was also used to map to EQ-5D-Y.
There were 17 (7%) mapping functions that used adult general population samples, two used women and one used school children with no specified conditions. The rest of the mapping functions were based on patient samples (n = 213, 91%). Clinical trials were the most common source of data. Respondents were also recruited from populations in the community, hospital and primary care. The two most common patient populations were cancer (n = 38, 16%) and rheumatoid or osteoarthritis (n = 23, 10%). Some populations were mixed, for example, Chen [62] and Richardson [63] used the Multi-instrument Comparison (MIC) dataset [253] , which has all the generic PBMs and contains both patients (self-identified) and members of the general population who were healthy. A number of studies relied on the MIC dataset to undertake mapping within specified patient populations including asthma [69, 212] , depression [64] , diabetes [65, 202] , cancer [205] and heart disease [68] .
Sample sizes varied widely. The smallest sample size was 30 respondents [81] while the largest was over 130,000 respondents [161] , both of which were mapping functions to the EQ-5D-3L. However, very few mapping functions used a sample size that was less than 100 (n = 10, 4%).
Estimation
The majority of functions mapped only to the HSUV index for the respective measures (n = 191, 82%). A few mapping functions were only to the PBM dimensions (n = 4, 2%), which were all mapping to EQ-5D-3L/EQ-5D-5L. The rest were mapping functions to both the HSUV index and PBM dimensions (n = 38, 16%), of which 32 were mapping to EQ-5D measures, four to SF-6D, one to HUI3 and one to CHU-9D. For the 15D, AQoL-4D/AQoL-8D and QWB-SA, all the mapping functions were only to the HSUV index.
The specific country value set used was restricted by available value sets for 15D (Finnish 2 ), AQoL (Australian) and QWB-SA (USA). One CHU-9D mapping function was to the Australian HSUV index [60] , while the rest used the UK HSUVs. One HUI3 mapping function was to the Spanish HSUV index [133] , while the rest were to the Canadian HSUVs. Three SF-6D mapping functions were to the Hong Kong HSUV index [220, 227, 229] , while the rest were to UK values. There were 85 mapping functions that used the EQ-5D-3L UK country HSUV, with 12 of these using these values alongside another country HSUVs. Other EQ-5D-3L country HSUVs that were used included the Canadian, USA, Chinese, Dutch, European, German, Japanese, Korean, Spanish and Swedish value sets (Appendix 2). The English value set was used in eight mapping functions for the EQ-5D-5L, while the UK cross-walk was used for five mapping functions. EQ-5D-5L mapping functions also used new value sets for the Netherlands, Spain, Canada, Uruguay, China, Japan and Korea as well as cross-walk values for USA and the Netherlands.
Most mapping functions used more than one regression method (n = 142, 61%). The most common regression method used when mapping to HSUVs was OLS, which was used in all the mapping functions for CHU-9D and most of the mapping functions (≥ 75%) for the other PBMs ( Table 1 ). Note that this does not necessarily reflect whether or not OLS is the most appropriate method. Other methods included those that aimed to take into account the limited range of the utility values such as CLAD and Tobit in addition to beta regressions and fractional logistic models. Generalised linear models that provide flexibility in the choice of the underlying distribution were also used. Robust regressions using the MM-estimator designed to deal with the potential impact of outliers in linear regressions were also used [254] . There were also models that allowed even greater flexibility such as mixture models, which enable a mixture of distributions in the regressions when estimating HSUVs. Finally, models combined different regression approaches such as OLS and logit regressions in two-or three-part models specified by the analyst with results combined post-analysis. The different 'parts' were determined by the distribution of the HSUVs, for example those who had in full health (HSUV = 1) versus those who had decrements in HRQoL (HSUV < 1). These two-or three-part models are similar to mixture models in that they attempt to address distribution of HSUVs. Methods such as the ALDVMM combined consideration of the distribution of the data and the limited rage of HSUVs [203] .
EQ-5D measures and SF-6D had the largest number of regression approaches applied when mapping to the HSUVs index (n = 19 and n = 17, respectively; Table 1 ) followed by HUI measures (n = 11), CHU-9D (n = 8), 15D and AQoL measures (n = 6 each) and QWB-SA (n = 5). For response mapping to PBM dimensions, ordered/multinomial/multivariate/generalised/partial proportional logit or probit regressions were undertaken. Response mapping was undertaken for EQ-5D measures (n = 32), HUI3 (n = 1), SF-6D (n = 3) and CHU-9D (n = 1).
Specification and Performance
In addition to the HRQoL source measures, age was included as a potential predictor in 51% (n = 119) of the reported mapping functions while gender was included in 55% (n = 126). Clinical outcomes such as body mass index (BMI) were included 20% (n = 46) of the time ( Table 2 ).
The majority of the mapping functions (n = 224, 96%) reported the model coefficients either in the paper or provided a way to generate the HSUV via a separate method such as an excel sheet or program. Some mapping functions were provided in separate programs to estimate HSUVs, for example Adams et al. [132] . Some papers using Bayesian networks did not report regression coefficients, for example Borchani et al. [164] . Other papers did not report coefficients because the authors judged that the results were not suitable for use as mapping functions due to poor performance. For example, both Bafus et al. [81] and Dzingina et al. [163] found that there were large differences between observed and predicted values.
Most of the mapping functions (n = 192, 82%) had overall MAE, MSE or RMSE as part of the assessment of performance (Table 2) . Performance across different categories of severity was reported in 92 (39%) mapping functions, while plots were provided for 120 mapping functions (52%). Plots included scatter or linear plots of observed against predicted HSUVs with or without errors and plots of the start measure against observed and predicted HSUVs.
Discussion
This review identified 180 papers that met the inclusion criteria. The studies undertook a range of different regression methods, with the HSUV index as the most common dependent variable. Most of the start measures were nonpreference-based measures with many studies including age and gender, while a more limited number also included clinical measures such as BMI. Most of the studies assessed performance using MAE, RMSE or MSE, while some studies also included plots of predicted HSUVs against the observed HSUVs or start measures, rather than relying on R-squared statistics as reported in the previous review [29] .
There were 180 mapping papers with 233 mapping functions identified over the review period (2007-2018) compared to 30 papers that were included in the previous review (1996-early 2007) [29] . This reflects the growth in mapping studies that has taken place in the last decade. Half (n = 15) of the mapping functions included in the previous review were mapping to EQ-5D, whereas functions mapping to EQ-5D measures are reported in more than half (n = 147, 63%) of the mapping functions in this current review. This may reflect the recommendation to use EQ-5D and acceptance by NICE [18] of mapped HSUVs in their methods guide for HTA, which may have driven demand for mapping to EQ-5D. EQ-5D-3L is also the most widely used generic PBM.
Other PBMs had less mapping functions in both the previous review (HUI measures n = 8, 27%; SF-6D n = 5, 17%; AQoL measures n = 2, 7%; QWB-SA and 15D n = 1, 3%) and this review (HUI measures n = 13, 6%; SF-6D n = 45, 19%; AQoL measures n = 12, 5%; 15D n = 8, 3% and QWB-SA n = 4, 2%). There has been an increase in the number of mapping functions to the SF-6D in this review compared to the previous review. Although there are a number of mapping functions available for 15D, AQoL measures, HUI measures and QWB-SA, many of the mapping functions rely on the same dataset, the MIC dataset. In addition, this current review included mapping functions to the CHU-9D, which was under development during the last review. One EQ-5D mapping function was to the EQ-5D-Y, but no other mapping functions to child or adolescent generic PBMs were identified.
Patient populations were the main type of datasets used to estimate the mapping functions (n = 213, 91%), rather than members of the general population, which was also the case in the previous review-where 20 (67%) papers used patient populations. The use of patient populations is potentially better suited to address concerns regarding using appropriate populations to generate mapping functions in terms of demographic characteristics as well as severity [27] . However, where the source is trial data rather than registry data, this may result in a small sample size. Trial data may also reflect very specific characteristics such as severity levels due to trial inclusion criteria. This can be useful if a mapping function is to be used in a similar population, but may be restrictive if mapping functions are being applied in trials with different inclusion criteria or real-world populations. The growing use of HSUVs and generic PBMs has led to growth in the inclusion of these types of measures in routine use, for example as part of routine measures following hip and knee replacements in England [255] or registry data [256] , which provide larger datasets of individuals who have received care. This offers alternative sources of data that can be used to undertake mapping as well as to test performance of mapping functions in the future. The most common regression method to estimate mapping functions mapping to the HSUV index was OLS in both reviews. Brazier et al. [29] noted that OLS shows a systematic pattern in over-predicting at the lower end and underpredicting at the upper end of HSUVs, and that alternative approaches should be tested. The previous review had one study that used Tobit and two used CLAD to address the bounded nature of HSUVs, while less restrictive linear models such as the generalised linear model (GLM) were also used [29] . In the current review, most mapping functions were estimated using more than one regression method (n = 142, 61%). In addition to CLAD, Tobit and GLM, which were used in the earlier review, other methods commonly included in this review were two-/three-part models, beta regressions, fractional logistic regressions and mixture models. EQ-5D measures and SF-6D had the largest number of regression approaches applied when mapping to the HSUVs index, which reflects where mapping was used. For EQ-5D-3L, methods to address the distribution of the UK values, which have a multi-modal distribution with a large proportion of values at 1 and a gap between 1 and the next value (i.e. 0.883), has also increased the number of approaches used. For example, methods such as ALDVMM have been developed to address the specific nature of the EQ-5D-3L UK value set [128] . These are aimed at replicating not only mean predicted HSUVs but also the distribution of the HSUVs index. These regression methods can be extended to mapping to EQ-5D HSUVs from other country value sets as well as other measures; for example, Gray et al. [212] use these approaches for HUI3. The appropriateness of methods will depend on the measure and distribution as well as standard tests applied to assess these methods. For example, the SF-6D UK value set has a limited range but does not have the multimodal distribution that is seen in the UK EQ-5D-3L value set, which can impact on model selection.
Response mapping was undertaken using ordered or multinomial probit or logit regressions, with five (17%) studies reported using this approach in the previous review, which was a similar proportion to the current review (16%, n = 37). All the studies in the previous review used response mapping to map to EQ-5D-3L. Response mapping has also mainly been undertaken for the EQ-5D measures (n = 32) in the current review. An additional three mapping functions to SF-6D, one to HUI3 and CHU-9D, used response mapping in the current review. Application of response mapping across all measures remains relatively low with the exception of EQ-5D measures. This reflects both the number of dimensions in the measure and the availability of large samples that cover the range of severity within each dimension.
Most mapping functions (n = 192, 82%) in this review reported MAEs or RMSEs to assess the performance of mapping functions. These statistics were supported by examining errors by severity to assess whether there were systematic patterns in the errors (n = 92, 39%) or plots of observed HSUVs or predicted HSUVs and errors (n = 120, 120%). This is an improvement on the previous review where the pattern of errors was only reported in two studies (7%) [29] .
Regression coefficient values, which are important if mapping functions are to be applied in external datasets, were reported for most of the mapping functions (96%). Some mapping functions were provided in separate programs to estimate HSUVs, which was useful particularly where standard OLS techniques were not used, therefore coefficient values could not simply be applied directly to the external dataset. Some papers did not report coefficient results because the authors judged that mapping functions performed poorly based on predictive ability. Although most papers reported coefficients alongside assessment of performance of models, validity of mapping functions will depend on other information such as the mapping dataset and how it compares to the dataset where mapping functions will be applied. For example, Woodcock et al. [110] found that there 13 (29) 25 (56) 27 (60) 44 (98) 39 (87) 18 (40) 28 (62) Total (n = 233)
46 (20) 119 (51) 128 (55) 224 (96) 192 (82) 92 (39) 120 (52) were differences in which mapping function was preferred when they were applied to different datasets.
Although this review provides a useful resource for analysts, there are some limitations. There was no quality assessment of the included studies, and no judgement of whether regression methods, model specifications or predictive ability were appropriate. Any judgements on quality cannot be generalised as the appropriateness of mapping functions relies on assessment of applicability for the context while appropriateness of methods relies on the target PBM. Though the aim of this review was not to examine whether published studies are in accordance with published recommendations including recent ISPOR Taskforce guidelines [27] , our extracted data enable a general assessment of whether important information is reported. Our findings suggest that since the 2010 review [29] authors have increased the number of regression methods that they use as well as their reporting of predictive ability of mapping functions across different categories of severity. Despite OLS remaining the most commonly used regression method, there has been a wider use of other regression methods that are likely to be more appropriate for the distribution of HSUV data. This is a promising development since the 2010 review as it suggests that researchers are taking into account the distribution of their data.
Where mapping is required to generate HSUVs to inform HTA, the widespread availability of mapping functions estimated using patient populations rather than the general population is likely to mean that the datasets used to estimate mapping functions are most similar to the clinical trial or observational datasets to which they are applied. This may in turn lead to reduced error in mapped HSUVs. In addition, the availability of more published mapping functions may allow their performance to be tested in separate datasets. For example, a number of mapping functions are available for the EORTC-QLQ-C30 to EQ-5D-3L, which allows them to be tested against each other. For example, Woodcock et al. [110] tested five existing EORTC QLQ-C30 mapping functions.
Acceptability to generate HSUVs using mapping in HTA submissions to international agencies has increased since the previous review, which is likely to have encouraged the proliferation of mapping studies. This acceptability is also reflected in the use of the cross-walk mapping algorithm [40] from EQ-5D-5L to EQ-5D-3L as an official scoring approach by the EuroQoL group. This cross-walk algorithm can potentially be applied to any other studies that already have EQ-5D-3L HSUVs but not EQ-5D-5L utility values, as has been done for Poland [42] and Sri-Lanka [41] . As there are many more EQ-5D-3L country value sets than EQ-5D-5L, this offers an interim alternative to generating EQ-5D-5L values.
New developments in models that take into account the distribution of HSUVs and greater understanding of how the use of mapping in economic evaluation impacts on incremental cost-effectiveness ratios enable the science to be both better undertaken and better understood. However, there is still room for improvement and cause to apply caution. Authors are encouraged to follow published recommendations around mapping best practice [25] [26] [27] 30] , including the recent ISPOR Taskforce guidelines [27] . It is recommended that error term distributions, variance and covariance are reporting in mapping studies to enable better understanding of the accuracy of mapped estimates when they are used in cost-effectiveness modelling [26, 27] . It is also recommended that a plot (with values reported in a table) is always included of predicted versus observed HSUVs conditional on the start measure, to enable researchers using the mapping function to understand the potential accuracy of the mapped estimates [27] . It is hoped that the mapping literature will take these recommendations on board over the coming decade.
Mapping is not guaranteed to generate accurate mapped HSUVs. Care must be taken to ensure overlap between the measures that are mapped from and to as if the generic preference-based measure is inappropriate in that patient population mapping to this measure is also inappropriate. Mapping should not be used to avoid including a generic preferencebased measure in a trial or key observational study since mapped estimates increase uncertainty and are not preferable to direct administration of the preference-based measure.
In conclusion, this review provides an important resource for researchers enabling the identification of possible mapping studies for use to predict HSUVs for a range of different conditions and for a range of different preference-based measures.
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